A step forward that could influence how smart contracts are designed and verified.
Updated
January 8, 2026 6:32 PM
ChainGPT's robot mascot. IMAGE: CHAINGPT
A new collaboration between ChainGPT, an AI company specialising in blockchain development tools and Secret Network, a privacy-focused blockchain platform, is redefining how developers can safely build smart contracts with artificial intelligence. Together, they’ve achieved a major industry first: an AI model trained exclusively to write and audit Solidity code is now running inside a Trusted Execution Environment (TEE). For the blockchain ecosystem, this marks a turning point in how AI, privacy and on-chain development can work together.
For years, smart-contract developers have faced a trade-off. AI assistants could speed up coding and security reviews, but only if developers uploaded their most sensitive source code to external servers. That meant exposing intellectual property, confidential logic and even potential vulnerabilities. In an industry where trust is everything, this risk held many teams back from using AI at all.
ChainGPT’s Solidity-LLM aims to solve that problem. It is a specialised large language model trained on over 650,000 curated Solidity contracts, giving it a deep understanding of how real smart contracts are structured, optimised and secured. And now, by running inside SecretVM, the Confidential Virtual Machine that powers Secret Network’s encrypted compute layer, the model can assist developers without ever revealing their code to outside parties.
“Confidential computing is no longer an abstract concept,” said Luke Bowman, COO of the Secret Network Foundation. “We've shown that you can run a complex AI model, purpose-built for Solidity, inside a fully encrypted environment and that every inference can be verified on-chain. This is a real milestone for both privacy and decentralised infrastructure”.
SecretVM makes this workflow possible by using hardware-backed encryption to protect all data while computations take place. Developers don’t interact with the underlying hardware or cryptography. Instead, they simply work inside a private, sealed environment where their code stays invisible to everyone except them—even node operators. For the first time, developers can generate, test and analyse smart contracts with AI while keeping every detail confidential.
This shift opens new possibilities for the broader blockchain community. Developers gain a private coding partner that can streamline contract logic or catch vulnerabilities without risking leaks. Auditors can rely on AI-assisted analysis while keeping sensitive audit material protected. Enterprises working in finance, healthcare or governance finally have a path to adopt AI-driven blockchain automation without raising compliance concerns. Even decentralised organisations can run smart-contract agents that make decisions privately, without exposing internal logic on a public chain.
The system also supports secure model training and fine-tuning on encrypted datasets. This enables collaborative AI development without forcing anyone to share raw data—a meaningful step toward decentralised and privacy-preserving AI at scale.
By combining specialised AI with confidential computing, ChainGPT and Secret Network are shifting the trust model of on-chain development. Instead of relying on centralised cloud AI services, developers now have a verifiable, encrypted environment where they keep full control of their code, their data and their workflow. It’s a practical solution to one of blockchain’s biggest challenges: using powerful AI tools without sacrificing privacy.
As the technology evolves, the roadmap includes confidential model fine-tuning, multi-agent AI systems and cross-chain use cases. But the core advancement is already clear: developers now have a way to use AI for smart contract development that is fast, private and verifiable—without compromising the security standards that decentralised systems rely on.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.